Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma

British Journal of Cancer

Volumn 108, Issue 11, 2013, Pages 2312-2320

  Yoshimine, S ^a   Kikuchi, E ^a   Kosaka, T ^a   Mikami, S ^a   Miyajima, A ^a   Okada, Y ^a   Oya, M ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Animal model; Bafilomycin; Bcl xL; Prognostic factor; Upper urinary tract; Urothelial carcinoma

Indexed keywords

BAFILOMYCIN A1; MOLECULAR MARKER; PROTEIN BCL XL; BAFILOMYCIN A; BCL2L1 PROTEIN, HUMAN; MACROLIDE; PROTEIN BCL X;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; URETER TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BCL-X PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROLIDES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; URETERAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884187921     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.216     Document Type: Article

References (39)

1. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
2. Bolenz C, Weiss C, Wenzel M, Gabriel U, Steidler A, Becker A, Herrmann E, Trojan L, Michel MS (2009) In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma. J Cancer Res Clin Oncol 135: 679-686.
3. Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC (2007) Behavior of urothelial carcinoma with respect to anatomical location. J Urol 177: 1715-1720.
4. Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-507.
5. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998) The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448.
6. Fromont G, Roupret M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O (2005) Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol 48: 764-770.
7. Gabriel U, Bolenz C, Becker A, Schaaf A, Steidler A, Trojan L, Weiss C, Michel MS (2008) Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma. Oncol Rep 20: 1419-1423.
8. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52: 594-601.
9. Jeong IG, Kim SH, Jeon HG, Kim BH, Moon KC, Lee SE, Lee E (2009) Prognostic value of apoptosis-related markers in urothelial cancer of the upper urinary tract. Hum Pathol 40: 668-677.
10. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, Wei D (2012) Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem 113: 810-814.
11. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132.
12. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF (2007) Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 8: 128-136.
13. Karczmarek-Borowska B, Filip A, Wojcierowski J, Smolen A, Korobowicz E, Korszen-Pilecka I, Zdunek M (2006) Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 51: 61-69.
14. Kashibuchi K, Tomita K, Schalken JA, Kume H, Yamaguchi T, Muto S, Horie S, Kitamura T (2006) The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol 49: 839-845.
15. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M, Weider J (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34.
16. Kirsh EJ, Baunoch DA, Stadler WM (1998) Expression of bcl-2 and bcl-X in bladder cancer. J Urol 159: 1348-1353.
17. Korkolopoulou P, Lazaris A, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P (2002) Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 41: 274-283.
18. Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, Oya M (2010) Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion. Clin Cancer Res 16: 5814-5823.
19. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576.
20. Kunze D, Kraemer K, Erdmann K, Froehner M, Wirth MP, Fuessel S (2012) Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol; e-pub ahead of print 6 July 2012; doi:103892/ijo.2012.1549.
21. Lebedeva I, Raffo A, Rando R, Ojwang J, Cossum P, Stein CA (2001) Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 166: 461-469.
22. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6: 678-686.
23. Miyata Y, Kanda S, Nomata K, Eguchi J, Kanetake H (2005) Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173: 56-60.
24. Morimura T, Fujita K, Akita M, Nagashima M, Satomi A (2008) The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma. Pediatr Surg Int 24: 1087-1094.
25. Nakanishi K, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Matsuyama S, Matsuyama T, Kawai T (2005) Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res 11: 2583-2590.
26. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, Aurues T, Hayashi T, Ikeda T (2002) Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 441: 559-563.
27. Nakanishi K, Tominaga S, Kawai T, Torikata C, Aurues T, Ikeda T (1998) Expression of bcl-2 oncoprotein in transitional cell carcinoma of the upper urinary tract. Virchows Arch 432: 445-450.
28. Nakashima S, Hiraku Y, Tada-Oikawa S, Hishita T, Gabazza EC, Tamaki S, Imoto I, Adachi Y, Kawanishi S (2003) Vacuolar H+-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem 134: 359-364.
29. Ohta T, Arakawa H, Futagami F, Fushida S, Kitagawa H, Kayahara M, Nagakawa T, Miwa K, Kurashima K, Numata M, Kitamura Y, Terada T, Ohkuma S (1998) Bafilomycin A1 induces apoptosis in the human pancreatic cancer cell line Capan-1. J Pathol 185: 324-330.
30. Oosterlinck W (2007) Ureteral tumour: a specific upper urinary tract transitional cell carcinoma. Eur Urol 51: 1164-1165.
31. Rey A, Lara PC, Redondo E, Valdes E, Apolinario R (1997) Overexpression of p53 in transitional cell carcinoma of the renal pelvis and ureter. Relation to tumor proliferation and survival. Cancer 79: 2178-2185.
32. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial crcinoma following radical surgery. Eur Urol 62: 677-684.
33. Sasazawa Y, Futamura Y, Tashiro E, Imoto M (2009) Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci 100: 1460-1467.
34. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP (2004) p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22: 1014-1024.
35. Soltani-Arabshahi R, Leboeuf C, Rivet J, Pisonero H, Zhao WL, Bachelez H, Ameisen JC, Janin A (2009) Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J Invest Dermatol 129: 1703-1709.
36. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, Efferth T, Trauner D, Vollmar AM (2013) Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem 288: 1385-1396.
37. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N (2004) Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135: 604-612.
38. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR (2005) Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 96: 287-295.
39. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C (2004) Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 63: 1079-1083.